CMS Policy for Alabama, Georgia, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia

Local policies are determined by the performing test location. This is determined by the state in which your performing laboratory resides and where your testing is commonly performed.

Coverage Indications, Limitations, and/or Medical Necessity

This contractor will provide limited coverage for Gastrointestinal Pathogen (GIP) molecular assays identified by multiplex nucleic acid amplification tests (NAATs), and will limit GIP coverage in immune competent beneficiaries up to 5 bacterial targets which represent the top 90-95% of foodborne infections ([incidence of infection per 100,000 population]in decreasing incidence): Salmonella [15.89]; Campylobacter [12.97]; Shigella [5.53]; Cryptosporidium [3.31]; Shiga toxin producing E. coli (STEC) non-O157 [1.64] and STEC O157 [0.95].

In addition, when there is a clinical concern for Clostridium difficile colitis, this contractor will cover up to 11 targets if Clostridium difficile is one of the organisms tested for.

Testing for 12 or more organisms will only be covered in critically ill or immunosuppressed patients.

In immune competent individuals, most people with Cryptosporidium, a parasitic disease, will recover without treatment. The pathogens in some of the GIP panels are determined by the manufacturers that make them, and do not represent specific pathogens that cause a common age-based syndrome, or represent organisms that commonly are found in a specific sample type, patient population or reflect community acquired foodborne infections. Because of the unique clinical circumstances of immune compromised patients, ICU patients, and HIV positive patients with diarrhea, GIP testing for bacteria, virus and parasite testing may be indicated, and thus a Medicare benefit.

FDA-approved GIP Assays:

Five FDA approved GIP assays are currently on the market, and all are closed system tests that do not allow random access for physician’s to select likely etiologic agents of diarrhea. These include:

- **Hologic/Gen-Probe’s ProGastro SSCS:**
  - Targets identified:
    - Salmonella,
    - Shigella,
    - Campylobacter (C. jejuni and C. coli only, undifferentiated) nucleic acids, and
    - Shiga toxin 1 (stx1) /Shiga toxin 2 (stx2) genes (STEC typically harbor one or both genes that encode for Shiga toxins 1 and 2)
  - TAT (turn-around time) - 4 hr.

- **BD Diagnostics’ BD MAX Enteric Bacterial Panel (EBP):**
  - Targets identified:
    - Campylobacter spp. (jejuni and coli),
    - Salmonella spp.,
    - Shigella spp.,
    - Enterohemorrhagic E.coli (EHEC)
    - Shiga toxin 1 (stx1)/Shiga toxin 2 (stx2) genes (found in STEC, as well, as Shigella dysenteriae)
  - TAT – 3-4 hr.
JM Palmetto – Foodborne Gastrointestinal Panels Identified by Multiplex Nucleic Acid Amplification (NAATs)

CPT: 87505, 87506, 87507, 0097U

CMS Policy for Alabama, Georgia, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia (continued)

- Nanosphere’s Verigene Enteric Pathogens (EP):
  - Targets identified:
    - Campylobacter spp. (jejuni and coli), Campylobacter Group (comprised of C. coli, C. jejuni, and C. lari),
    - Salmonella species
    - Shigella species (including S. dysenteriae, S. boydii, S. sonnei and S. flexneri),
    - Vibrio Group (comprised of V. cholera and V. parahaemolyticus),
    - Yersinia enterocolitica,
    - Shiga toxin I gene and Shiga toxin 2 gene virulence markers, Shiga toxin-producing E coli (STEC)
    - Norovirus
    - Rotavirus
  - TAT – 2 hr.

- Luminex’s xTAG Gastroenterology Pathogen Panel (GPP):
  - Targets identified:
    - Campylobacter (C. jejuni, C. coli and C. lari only)
    - Clostridium difficile (C. difficile) toxin A/B
    - Cryptosporidium (C. parvum and C. hominis only)
    - Escherichia coli (E. coli) O157
    - Enterotoxigenic E. coli (ETEC) LT/ST
    - Giardia (G. lamblia only) (aka G. intestinalis and G. duodenalis)
    - Norovirus GI/GII
    - Rotavirus A
    - Salmonella
    - Shiga-like Toxin producing E. coli (STEC) stx 1/stx 2
    - Shigella (S. boydii, S. sonnei, S. flexneri and S. dysenteriae)
    - E. histolytica
    - Adenovirus 40/41
    - Vibrio cholera
  - TAT – <5 hr.

Visit QuestDiagnostics.com/MLCP to view current limited coverage tests, reference guides, and policy information.
To view the complete policy and the full list of medically supportive codes, please refer to the CMS website reference.
Biofire Diagnostic’s FilmArray GI Panel:
- Targets identified:
  - Campylobacter (C. jejuni/C. coli/C. upsaliensis),
  - Clostridium difficile (C. difficile) toxin A/B,
  - Plesiomonas shigelloides,
  - Salmonella,
  - Vibrio (V. parahaemolyticus/V. vulnificus/V. cholerae), including specific identification of Vibrio cholera,
  - Yersinia enterocolitica,
  - Enteraggregative Escherichia coli (EAEC),
  - Enteropathogenic Escherichia coli (EPEC),
  - Enterotoxigenic Escherichia coli (ETEC) it/st,
  - Shiga-like toxin-producing Escherichia coli (STEC) stx1/stx2 (including specific identification of the E. coli O157 serogroup within STEC),
  - Shigella/ Enteroinvasive Escherichia coli (EIEC),
  - Cryptosporidium,
  - Cyclospora cayetanensis,
  - Entamoeba histolytica,
  - Giardia lamblia (also known as G. intestinalis and G. duodenalis),
  - Adenovirus F 40/41,
  - Astrovirus,
  - Norovirus GI/GII,
  - Rotavirus A,
  - Sapovirus (Genogroups I, II, IV, and V)
- TAT – 1-2 hr.

All targeted viruses included in GIPs are more prevalent in young children than in adults. In one study, Sapovirus was detected in 10% of all specimens from children >1 year old and 7.4% of specimens from children between 1 to 5 years of age. Enteropathogenic E. coli (EPEC), historically associated with developing countries, are known to cause both acute and persistent diarrhea in 2 young children in the US and were identified in one study in 24.8% of all samples collected from children <1 year of age, and 37% of all samples from children between age of 1 and 5 years. EPEC strains can also be found in healthy children and adults, thus confounding its significance when identified in symptomatic children and adults.

Similarly, the interpretation of C. difficile toxin A/B detection is also complicated, especially in children <1 year old. The American Academy of Pediatrics does not recommend routine testing for C. difficile in children <1 year of age and suggests that positive C. difficile results be interpreted with suspicion in children <3 years old.

Most recently a publication looking at Syndromic Panel-Based Testing, specifically the multiplex detection of GI pathogens, states that it makes it difficult the interpretation of a positive results in asymptomatic individuals colonized with C. difficile. Patients experiencing diarrhea associated with antecedent of antibiotic or hospitalization are at risk for C. difficile infection; in such cases specific testing for C. difficile is most cost-effective. GIP’s detection of multiple targets has created confusion for healthcare providers that now faced with results that were not previously reported and for which current guidelines provide no direction as to management (treatment, clinical significance or the need for additional or repeat testing).
A meta-analysis (of 10 studies) by NHS in UK found that GIP testing produces a greater number of pathogen-positive findings than conventional testing. It is unclear whether or not these additional “positives” are clinically important. The review identified no robust evidence to inform consequent clinical management of patients. There is considerable uncertainty about cost-effectiveness of GIP panels used to test for suspected infectious gastroenteritis in hospital and community settings. The systemic review and cost-effectiveness model identify uncertainties about the adoption of GIP tests. GIP testing will generally identify pathogens identified by conventional testing, however, these tests also generate considerable additional positive results of uncertain clinical importance.

Indications for Foodborne GI Testing

Acute diarrhea, often called gastroenteritis, can be defined as the passage of a greater number of stools of decreased form from the normal lasting < 14 days. Acute diarrhea is generally associated with clinical features of nausea, vomiting, abdominal pain and cramps, bloating, flatulence, fever, passage of bloody stools, tenesmus and fecal urgency. It is the leading cause of outpatient visits, hospitalizations, and lost quality of life occurring domestically and those traveling abroad. The Centers for Disease Control and Prevention (CDC) has estimated 47.8M cases occurring annually in the US with an estimated healthcare cost upwards of US$150M. Detection of microbial pathogens associated with GI disease may be important in certain populations, such as immunocompromised hosts, the critically ill and individuals with prolonged disease that is refractory to treatment.

Over a 20 year period, some foods that have been linked to food-borne outbreaks including milk (Campylobacter), shellfish (Noroviruses), unpasteurized apple cider (Escherichia coli O157:H7), raw and undercooked eggs (Salmonella), fish (ciguatera poisoning), raspberries (Cyclospora); strawberries (Hepatitis A virus); and ready-to-eat meats (Listeria).

Although the etiologic agents responsible for about 80% of GI illnesses are unidentified or otherwise unspecified, Norovirus and Salmonella spp (non-typhoidal) are currently the most commonly identified pathogens associated with food-borne disease in the US and account for 5.5 and 1.0 million cases each year, respectively. Clostridium perfringens, Campylobacter and Staphylococcus aureus follow Norovirus and Salmonella spp. in decreasing frequency in domestically acquired foodborne illnesses. Healthcare- and antibiotic-associated diarrhea is also problematic, with the major causative pathogen being toxin-producing Clostridium difficile. Over 300,000 cases of C. difficile are diagnosed annually, with associated costs of >$1 billion.

In 2015, the number and incidence of confirmed infections per 100,000 population were reported for Salmonella (15.89), Campylobacter (12.97), Shigella (5.53), Cryptosporidium (3.31), Shigatoxin producing Escherichia coli (STEC) non-O157 (1.64), STEC O157 (.95), Vibrio (0.39), Yersinia (0.29), Listeria (0.24) and Cyclospora (0.13). Among confirmed infections, the vast majority were diagnosed only by culture. Compared with incidence in 2012-2014, the incidence of confirmed infections was significantly higher for STEC non-O157 (40% increase) and Cryptosporidium (57% increase). No significant changes were observed in 2015 for other pathogens compared with the previous 3-year averages. In addition to the 20,107 confirmed cases of infection, there were 3,112 positive CIDT case reports. In general, the incidence of most foodborne bacterial pathogens and for Cryptosporidium is highest among children aged <5, except for Listeria and Vibrio for which the highest incidence is among persons aged ≥ 65 years.

Many episodes of acute diarrhea are self-limited and require fluid replacement and supportive care. Oral rehydration is indicated for patients who are mildly to moderately dehydrated, IV fluids may be required for more severe dehydration. Routine use of antidiarrheal agents is not recommended because many of these agents have potentially serious adverse effects, particularly in infants and young children. Antimicrobial therapy is warranted only for patients with severe disease or for individuals with severely weakened immune systems are severely weakened from medications and other illnesses.
Laboratory testing algorithms for infectious causes of diarrhea generally agree that testing is NOT warranted for community-acquired diarrhea of <7 days duration without signs or symptoms of severe (fever, bloody diarrhea, dysentery, severe abdominal pain, dehydration, hospitalization and immunocompromised state) disease. In general, when community-acquired diarrhea persists for ≥7 days, or the diarrhea is travel-related, or there are signs/symptoms of severe disease, GIP testing may be warranted. Additional directed testing may be indicated if the GIP results are negative and diarrhea persists. No additional testing is indicated for GIP-positive result unless the clinical pictures changes. Clostridium difficile molecular testing is warranted on health-care associated diarrhea with onset after the 3rd inpatient day or after recent antibiotic use.

**Summary Medicare Coverage Decision:**

GIP testing is limited to no more than 5 bacterial pathogen targets when not testing for Clostridium difficile. Testing for 6-11 pathogens is covered when there is a clinical concern for Clostridium Difficile colitis, and Clostridium difficile is one of the pathogens being tested. Testing for viral etiologies is not reasonable and necessary because these GI diseases are generally self-limited, virus specific therapies are not available, and patients are managed by supportive care and hydration. Travelers with >2weeks of symptoms, after bacterial pathogens have been ruled out, may require traditional ova and parasite stool examination and/or specific protozoa antigen or molecular testing. Large panels inclusive of 11 viruses and protozoa are not reasonable and necessary for community-acquired diarrheal illness. There is no Medicare benefit for GIP testing for national, state or local agency tracking of diarrheal outbreaks, for epidemiologic purposes, or to confirm another etiologic test result. Once the target etiology of an outbreak is identified, subsequent patient testing is generally not indicated and patients are managed empirically. However, if the clinical presentation varies from the outbreak prototype, a specific test for the causative organism may be indicated. The Medicare benefit is specifically for the clinical identification and management of disease for a given beneficiary. The Medicare benefit does not extend for purposes of the family or community tracking or surveillance.

**Limitations**

A GIP test panel is a single service with a single unit of service (UOS =1). A panel cannot be unbundled and billed as individual components regardless of the fact that the GIP test reports multiple individual pathogens and/or targets. The panel is a closed system performed on a single platform, and as such, is a single test panel with multiple components (UOS=1). If C. difficile is not included in a GIP panel, testing for C. difficile may be reasonable and necessary when ordered in addition to a GIP bacterial pathogen panel and supported by documentation in the medical record.
To view the complete policy and the full list of medically supportive codes, please refer to the CMS website reference.

Visit [QuestDiagnostics.com/MLCP](https://www.QUESTDIAGNOSTICS.com/MLCP) to view current limited coverage tests, reference guides, and policy information.
The ICD10 codes listed below are the top diagnosis codes currently utilized by ordering physicians for the limited coverage test highlighted above that are also listed as medically supportive under Medicare’s limited coverage policy. If you are ordering this test for diagnostic reasons that are not covered under Medicare policy, an Advance Beneficiary Notice form is required.

*Note—Bolded diagnoses below have the highest utilization

### Code Description

**Group 1 Codes:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z94.4</td>
<td>Liver transplant status</td>
</tr>
<tr>
<td>Z94.0</td>
<td>Kidney transplant status</td>
</tr>
</tbody>
</table>

**Group 2 Codes:**

See Article A56593 for covered diagnosis codes.